Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- ARDS, Human
- COVID
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: A Randomized, Open-Label, Phase II TrialMasking: None (Open Label)Masking Description: Senicapoc-treated patients compared to standard treatmentPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The investigators discovered that in an animal model with a knockout of a potassium channel with intermediate conductance (KCa3.1), the knockout protected against lung damage and accumulation of liquid in the lung. In subsequent studies, the investigators have developed a mouse model showing that ge...
The investigators discovered that in an animal model with a knockout of a potassium channel with intermediate conductance (KCa3.1), the knockout protected against lung damage and accumulation of liquid in the lung. In subsequent studies, the investigators have developed a mouse model showing that genetic deletion of the KCa3.1 channels and senicapoc, a blocker of KCa3.1 channels, protects against the accumulation of liquid in the lung. Moreover, senicapoc treatment possesses anti-inflammatory effects illustrated as lower leukocyte accumulation inside the lungs after injury. Importantly, it also increases the FiO2/PaO2 ratio (ratio of inhaled to blood oxygen), hence preserving lung function in mice with an ARDS-like disease. In addition, there is evidence that senicapoc has antiviral properties. Aarhus University has patented senicapoc for use in the treatment of acute respiratory disease. In this case, respiratory disease is caused by an infection with a coronavirus. Senicapoc has been developed for the treatment of sickle cell disease and has been administered to 500 patients without observation of major treatment-related adverse effects.
Tracking Information
- NCT #
- NCT04594668
- Collaborators
- Aarhus University Hospital
- Odense University Hospital
- Aalborg University Hospital
- Hvidovre University Hospital
- Investigators
- Principal Investigator: Steffen Christensen, MD Aarhus University Hospital Principal Investigator: Thomas Strøm, MD Odense University Hospital Principal Investigator: Bodil S Rasmussen, MD, PhD Aalborg University Hospital Principal Investigator: Klaus T Kristiansen, MD Hvidovre University Hospital Study Chair: Asger Granfeldt, MD, PhD Aarhus University Hospital
Get Well Soon